ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 2074

Poor Executive Function Correlates with Increased Disease Damage and Impaired Patient-Reported Outcomes in Youth with Childhood-Onset Lupus: A Cross-Sectional Study

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1686

Post-translational Modification of Matrix-gla Protein with Malondialdehyde-Acetaldehyde Alters Cellular Responses by Human Fibroblasts

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 1703

Potential Regulation of NK Cells by CD1c+ Dendritic Cells Through RIG-I/DDX60 Pathway Involved in Th17 Responses in Primary Sjögren Syndrome

Innate Immunity Poster: Basic and Translational Science

1:00PM-3:00PM: Abstract Number: 2062

Predicting Severe Flares: Real-world Application of a Decision-Tree Model Among the Medicaid-Insured Systemic Lupus Erythematosus (SLE) Population in the US

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1955

Predictive Factor of Spontaneous Regression in Methotorexate-associated Lymphoproliferative Disorders with RA Patients

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 1989

Predictors of Flare in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 2094

Predictors of Health-Related Quality of Life (HRQoL) in Adults with Juvenile- and Adult-onset Systemic Lupus Erythematosus: Results from a Multiethnic US Cohort (LUMINA)

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 2067

Predictors of Organ Damage Accrual by Domains

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 2012

Predictors of Remission in Rheumatoid Arthritis Patients Treated with Biologics: A Systematic Review and Meta-analysis

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 1987

Prednisone Use and the Incidence of Hyperglycemia or Diabetes in Patients with Rheumatoid Arthritis; A 10-year Sub Analysis of the BeSt Study

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 2107

Pregnancy Outcomes Among Women with Systemic Lupus Erythematosus (SLE): Impact of Preexisting Hypertension

SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

1:00PM-3:00PM: Abstract Number: 1943

Prevalence and Evolution of Undifferentiated Periodic Fever Syndromes in an Academic Pediatric Rheumatology Practice

Pediatric Rheumatology – Clinical Poster III: Other

1:00PM-3:00PM: Abstract Number: 1770

Prevalence and Incidence of Depression in Patients with Rheumatoid Arthritis: A Systematic Review

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 1793

Prevalence of HLA B*5801 Allele Among African American Patients with Gout in an Academic Health Center

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 2164

Profibrotic Alveolar Macrophages as a Potential Biomarker in Systemic Sclerosis-associated Interstitial Lung Disease

Systemic Sclerosis and Related Disorders – Clinical Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].